BC
RETA

Brinker Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Brinker Capital’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-985
Closed -$201K – 1008
2019
Q4 		$201K Buy
+985
New +$180K 0.01% 932

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Brinker Capital's RETA Position: Q1 2020 in Review

Brinker Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2020, closing a stake of 985 shares — an estimated $201K sold.

Brinker Capital first reported a position in RETA in Q4 2019 and held it in 1 quarter. The position peaked at $201K in Q4 2019. 214 funds tracked by Wall St. Rank hold RETA as of Q1 2020.

  • Brinker Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2020 after selling out during the quarter.
  • Brinker Capital sold 985 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2020, an estimated $201K.
  • Brinker Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 1 quarter.
  • Brinker Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $201K in Q4 2019.
  • 214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2020.

Based on Brinker Capital's 13F filing for Q1 2020, filed 29 Apr 2020.